Impact of maximum standardized uptake value (SUVmax) evaluated by 18-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG-PET/CT) on survival for patients with advanced renal cell carcinoma: a preliminary report - Wikidata - awgldk - TriplyDB

Impact of maximum standardized uptake value (SUVmax) evaluated by 18-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG-PET/CT) on survival for patients with advanced renal cell carcinoma: a preliminary report

Impact of maximum standardized uptake value (SUVmax) evaluated by 18-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG-PET/CT) on survival for patients with advanced renal cell carcinoma: a preliminary report

http://www.wikidata.org/entity/Q33762689

about

The Place of FDG PET/CT in Renal Cell Carcinoma: Value and Limitations Update on advances in molecular PET in urological oncology Can Initial (18)F-FDG PET-CT Imaging Give Information on Metastasis in Patients with Primary Renal Cell Carcinoma?Evaluation of treatment response and resistance in metastatic renal cell cancer (mRCC) using integrated 18F-Fluorodeoxyglucose (18F-FDG) positron emission tomography/magnetic resonance imaging (PET/MRI); The REMAP study The early response of renal cell carcinoma to tyrosine kinase inhibitors evaluated by FDG PET/CT was not influenced by metastatic organ.Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course The maximum standardized uptake value of 18 F-FDG PET scan to determine prognosis of hormone-receptor positive metastatic breast cancer Management of urological malignancies: Has positron emission tomography/computed tomography made a difference?Clinically significant association between the maximum standardized uptake value on 18F-FDG PET and expression of phosphorylated Akt and S6 kinase for prediction of the biological characteristics of renal cell cancer Metabolic Characteristics of Advanced Biliary Tract Cancer Using 18F-Fluorodeoxyglucose Positron Emission Tomography and Their Clinical Implications FDG PET/CT as a prognostic biomarker in the era of molecular-targeting therapies: max SUVmax predicts survival of patients with advanced renal cell carcinoma.Prognostic Value of Quantitative Metabolic Metrics on Baseline Pre-Sunitinib FDG PET/CT in Advanced Renal Cell Carcinoma.Imaging techniques as predictive and prognostic biomarkers in renal cell carcinoma.FDG PET or PET/CT in evaluation of renal angiomyolipoma Alternate Metabolic Programs Define Regional Variation of Relevant Biological Features in Renal Cell Carcinoma Progression.Molecular imaging of urogenital diseases.The acceleration of glucose accumulation in renal cell carcinoma assessed by FDG PET/CT demonstrated acquisition of resistance to tyrosine kinase inhibitor therapy.Positron emission tomography/computed tomography imaging features of renal cell carcinoma and pulmonary metastases in a dog.Prognostic factors in patients with advanced renal cell carcinoma treated with VEGF-targeted agents.Metastatic renal cell carcinoma imaging evaluation in the era of anti-angiogenic therapies.Tyrosine-Kinase Inhibitors Therapies with Mainly Anti-Angiogenic Activity in Advanced Renal Cell Carcinoma: Value of PET/CT in Response Evaluation.Assessment of cell proliferation in renal cell carcinoma using dual-phase (18)F-fluorodeoxyglucose PET/CT Prognostic implication of extrarenal metabolic tumor burden in advanced renal cell carcinoma treated with targeted therapy after nephrectomy.Oncocytoma: A Differential Consideration for an Incidentally Detected FDG-Avid Renal Mass on PET/CT.PET-CT and PET-MR in urological cancers other than prostate cancer: An update on state of the art.One-month assessment of renal cell carcinoma treated by everolimus using FDG PET/CT predicts progression-free and overall survival.Comparison of 11C-4DST and 18F-FDG PET/CT imaging for advanced renal cell carcinoma: preliminary study.

P2860

Q28070239-3B2E2900-A172-4C62-840D-254159EC5C2A Q33625389-9A11A059-9F28-4B6B-A7E3-585868952626 Q33639383-68568A02-C6A4-49A6-BFD6-36318E917CD1 Q33755947-FBD5B05A-9F14-45D5-B511-4F48A0F7D38F Q33792683-FDAE5285-33C5-4273-AFC0-BB99AD72E17A Q34253776-52573A63-4EDA-4E45-8CC9-01DD2E14146B Q34569318-96142E6C-14D0-4FEF-9C96-8BA2014DA4C1 Q34990800-CEDDE2B6-3F45-4977-B5DF-30953EC208BD Q35169825-E5FFD772-2F0B-4F72-B771-BC18F057E18A Q35915703-DBF675AB-2F85-4492-9645-F96C11BB4402 Q35917780-768C5C16-FD04-47C6-9E38-9F67FA4211D1 Q36001780-9421FC7F-63A0-446B-99F0-F4A94F1C4D25 Q36567385-DE03C0B8-D98C-4B38-8332-8AE5D2968A90 Q36662636-5BF43BFA-0339-48C6-9E52-E4401C215E45 Q37014111-17C691D0-9308-4F7D-BD74-65AA63FBA1C1 Q37550399-20C2D865-CA97-4946-B2E1-AFE71B0782A5 Q37576212-D69F54CA-2CE0-4F02-AF81-A776F3B3964E Q37711287-69341C09-1F1E-4AD1-BD4E-7FA61353CC37 Q38196855-130AF44F-AD4A-4460-B03E-CE404C722647 Q38837758-0C5BE090-356A-490B-8210-05CC859D535B Q41660750-A4C150BF-7E5D-45E9-A73A-7487AB889A37 Q42363905-931AB395-95E1-425B-ADB2-979ABADED6A3 Q45823946-72DB2B4C-5EEE-446D-8FED-A1E0ACA316F3 Q47094599-CA1B9FB4-5ACE-4374-A7D9-466232349395 Q49165684-1B8DE2F2-4C7E-4A36-A762-5971468B3B26 Q52780316-D3002B90-E9F7-4082-91BD-8B660BF66AAF Q52877176-D49A325E-D235-4F74-B508-87F0E24B2589

P2860

Impact of maximum standardized uptake value (SUVmax) evaluated by 18-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG-PET/CT) on survival for patients with advanced renal cell carcinoma: a preliminary report

http://www.wikidata.org/entity/Q33762689

description

2010 nî lūn-bûn

@nan

2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Impact of maximum standardized ...... arcinoma: a preliminary report

@ast

Impact of maximum standardized ...... arcinoma: a preliminary report

@en

type

label

Impact of maximum standardized ...... arcinoma: a preliminary report

@ast

Impact of maximum standardized ...... arcinoma: a preliminary report

@en

prefLabel

Impact of maximum standardized ...... arcinoma: a preliminary report

@ast

Impact of maximum standardized ...... arcinoma: a preliminary report

@en

P1433

Q33762689-2076EB06-1D5B-48AB-B23C-AE3C3499AB00

P1476

Q33762689-B4839DCC-D7EF-407E-8763-3D70B0F8223E

P2093

Q33762689-2D25EE94-309E-453E-B7DF-A9959C7157E7

Q33762689-2E39DECB-F0EB-46BF-AB8E-131D5C5E6934

Q33762689-33AED07E-D072-4CC3-9884-AA040EEE66F2

Q33762689-5E37E1E9-B6D6-4EE5-92DD-67478ACF2108

Q33762689-6E8390B5-0361-4906-9C82-D33324EAD735

Q33762689-76F5FD57-8780-42F6-9349-3FCDBD64540B

Q33762689-78658809-83D1-40CE-AE98-675EF483B653

Q33762689-904529B4-4A3B-43D4-89FB-03431924A445

Q33762689-98E90B93-8764-48E5-B2D3-74719181769A

Q33762689-9CFFB742-E753-4940-8578-DC0046CF68DA

P2860

Q33762689-00486567-015A-4AF0-AB09-BE6DAE6ACB8B

Q33762689-07C18FCC-D0D4-445B-A695-9EC4850752FA

Q33762689-0F549BB8-C8F1-491D-923F-E4A4E55E788D

Q33762689-0FCD4D3C-4A45-4E33-9F22-19393DC89F19

Q33762689-1409E55F-B9B8-476A-893E-FF2B6A935CFA

Q33762689-2E924588-1448-422F-8759-BE60C0A30AC0

Q33762689-499CF5A9-5495-4F1A-A448-8B81FA72D26B

Q33762689-49C8298F-EC3F-4F57-BDEC-F924BF762651

Q33762689-4D32EA02-037A-4E55-9B98-DD81BE335567

Q33762689-4FF0F859-484D-476F-95A5-498AC8B83E56

P2888

Q33762689-EC24ADF4-9E06-4A23-9B0A-CE6DFE5CB510

P304

Q33762689-2FECD880-CB2F-4D76-9A14-9A73C0E0AA59

P31

Q33762689-163E58AF-8ED1-40FD-BC61-9FF7BE4D48B1

P356

Q33762689-CCDE8063-D823-44BF-A43D-9B728A54FDB9

P407

Q33762689-4E3BB8AC-8B39-436C-B0AB-9F387BEC6BB8

P478

Q33762689-CAAA0B12-FB1A-4499-8CF6-4CB84809C964

P577

Q33762689-F524DC42-3022-43B4-9E40-CF5EF6D92AD5

P5875

Q33762689-B100D180-1D05-4DD8-9C18-0F58ED620E6A

P6179

Q33762689-883A0F33-9D84-40E0-B488-509921131506

P698

Q33762689-B5DB4A30-A07E-4C14-9A4D-C3EC20C7D41F

P932

Q33762689-10E327AA-EC9D-42B8-BE76-27D4ED1A4247

P356

1471-2407-10-667

P1433

P1476

Impact of maximum standardized ...... arcinoma: a preliminary report

@en

P2093

Futoshi Sano

http://www.w3.org/2001/XMLSchema#string

Hanako Ishigaki

http://www.w3.org/2001/XMLSchema#string

Kazuhide Makiyama

http://www.w3.org/2001/XMLSchema#string

Kazuhiro Namura

http://www.w3.org/2001/XMLSchema#string

Kazuki Kobayashi

http://www.w3.org/2001/XMLSchema#string

Masahiro Yao

http://www.w3.org/2001/XMLSchema#string

Narihiko Hayashi

http://www.w3.org/2001/XMLSchema#string

Noboru Nakaigawa

http://www.w3.org/2001/XMLSchema#string

Ryogo Minamimoto

http://www.w3.org/2001/XMLSchema#string

Sumio Noguchi

http://www.w3.org/2001/XMLSchema#string

P2860

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

Sorafenib in advanced clear-cell renal-cell carcinoma

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.

Renal-cell carcinoma.

Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer

Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma.

Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial.

Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease.

P2888

1471-2407-10-667

P304

667

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2407-10-667

http://www.w3.org/2001/XMLSchema#string

P407

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

2010-12-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49655993

http://www.w3.org/2001/XMLSchema#string

P6179

1031120077

http://www.w3.org/2001/XMLSchema#string

P698

21129184

http://www.w3.org/2001/XMLSchema#string

P932

3016292

http://www.w3.org/2001/XMLSchema#string